Sanofi

Granite Bio is a biotechnology company focused on developing novel monoclonal antibody therapies targeting inflammatory, autoimmune, and fibrotic disorders.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Resalis Therapeutics focuses on treating metabolic diseases by targeting key regulators of pathways related to obesity and fatty liver disease. Its flagship program, RES-010, is a non-coding RNA drug modality designed for long-term weight loss and reduced hepatic steatosis.

EuroAPI develops, manufactures and supplies the active-ingredient solutions for healthcare.

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies. Its lead drug candidate, NB-4746, inhibits the SARM1 protein to prevent nerve damage in neurological diseases. The company aims to advance this therapy towards phase 1b/2 trials by 2025.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

We are a pharmaceutical company dedicated to improving access to medicine in East & Central Africa. We mainly focus on data-driven healthcare solutions that increase access and quality of information as well as facilitate safe, effective, and sustainable pharmaceutical supply chains across the industry. Our mission is to increase access to high-quality medicines, services, and information via technology solutions that improve affordability, health outcomes, and ease of use.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

SwipeRx is a digital platform designed for pharmacies that connects pharmaceutical manufacturers, pharmacies, and patients. It offers specialized healthcare logistics, negotiated pricing, and financing solutions, creating the largest digital pharmacy purchasing network. The platform generates insights that enhance collaboration among pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and boosts operational efficiencies, providing real-time access to patient and sales data. By doing so, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Nucleai Ltd. is a spatial biology company based in Tel Aviv-Yafo, Israel, founded in 2017. It has developed an AI-powered pathology platform that enhances drug development and improves patient outcomes by analyzing tissue datasets to provide insights into cancer biology. The platform is designed to detect various diseases, including cancer, prostate, breast, and gastrointestinal conditions, through advanced machine learning and computer vision techniques. By improving the interpretation of biopsies and supporting treatment decisions, Nucleai aims to increase the efficacy of clinical trials and enhance patient care. The company collaborates with leading pharmaceutical firms, licensing its technology for internal research and participating in biomarker discovery projects. Nucleai serves hospitals and laboratories primarily in the United States and Israel.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Origimm is an Austrian biotechnology company focused on discovering antigens and functional drug targets. The company develops innovative treatments aimed at preventing and treating infectious diseases, as well as dermatological conditions linked to skin-colonizing microbes.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Kadmon Holdings is a biopharmaceutical company focused on discovering, developing, and commercializing small molecules and biologics for the treatment of inflammatory and fibrotic diseases. Founded in 2010 and headquartered in New York, Kadmon's lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of rho-associated coiled-coil kinase 2, which is in Phase II clinical trials for chronic graft-versus-host disease and fibrotic diseases; KD045, an oral inhibitor of ROCK for fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for cancer treatment. The company also develops Tesevatinib for autosomal dominant polycystic kidney disease, ribavirin for hepatitis, and CLOVIQUE for Wilson’s disease. Kadmon has strategic collaborations with Nano Terra and Dyax Corp.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Medisafe is a digital platform empowering patients to manage their medications effectively. It leverages data science to personalize patient engagement, improving medication adherence by up to 20% as proven in studies. With nearly 5 million users across various devices and an average app rating of 4.7 stars, Medisafe facilitates medication tracking, reminders, and insights for patients and healthcare providers.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

BioNTech is a Germany-based biotechnology company focused on developing cancer therapeutics and vaccines for infectious diseases. Its portfolio includes mRNA-based therapies to encode antigens and neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. The company maintains an oncology pipeline and collaborates on vaccines for infectious diseases, including a COVID-19 vaccine developed with Pfizer.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

Ablynx is a biopharmaceutical company focused on discovering and developing Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These Nanobodies are designed to treat serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. The company currently has around 25 projects in its pipeline, with five Nanobodies in clinical development. Ablynx's products aim to combine the advantages of conventional antibodies and small chemical molecules, offering patients innovative therapeutic options that can significantly impact society.

Bioverativ Inc. is a biopharmaceutical company focused on developing therapies for hemophilia and other rare blood disorders, including cold agglutinin disease, sickle cell disease, and beta thalassemia. Founded in 2016 and headquartered in Waltham, Massachusetts, the company aims to transform the lives of patients through innovative research and development. Bioverativ's pipeline features hemophilia therapies that offer less-frequent prophylactic dosing for hemophilia A and subcutaneous dosing for hemophilia B, as well as gene therapy programs for both types of hemophilia. Additionally, the company is working on Sutimlimab, a treatment aimed at inhibiting the complement pathway of the immune system to address cold agglutinin disease. As a subsidiary of Sanofi, Bioverativ continues to advance its mission to provide effective treatments for chronic blood disorders.

Thermalin, Inc. is a biotechnology company based in Cleveland, Ohio, founded in 2010, that focuses on developing innovative insulin therapies for individuals with Type 1 and Type 2 diabetes. The company aims to transform the insulin and insulin delivery market, valued at $30 billion, through its cutting-edge, highly concentrated, ultra-rapid acting insulin and a novel glucose management system that is the size of a postage stamp. This insulin can also be utilized in existing insulin pumps, enhancing their efficiency. In addition to its lead program, Thermalin is exploring partnerships to create no-cold-chain basal and mix insulins, as well as glucose-responsive insulins. Its products are designed to be rapidly absorbing and do not require refrigeration, thereby reducing the burden of insulin therapy and improving patient adherence and health outcomes.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

ImmuneXcite, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of monoclonal antibodies for cancer treatment. Founded in 2007, the company utilizes its proprietary mAbXcite platform technology to enhance the efficacy of therapeutic monoclonal antibodies. This innovative approach involves chemically linking a unique carbohydrate, initially discovered at the Whitehead Institute at MIT, to monoclonal antibodies, thereby activating neutrophils to target and destroy cancer cells. ImmuneXcite's focus is on leveraging both innate and adaptive immune responses to create next-generation immune-activating biotherapeutics that address a wide range of tumor types, aiming to limit tumor growth and metastasis effectively. The company's research and development efforts have garnered support from various esteemed institutions and organizations, including the Massachusetts Technology Transfer Center and the National Cancer Institute.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Ovid Therapeutics is a biopharmaceutical company focused on developing impactful medicines for patients with neurological disorders. Established in 2014, the company's pipeline includes OV101 (in Phase III for Angelman syndrome), OV935 (in Phase II for CDKL5 deficiency disorder and Dravet syndrome), and other programs targeting rare epilepsies and seizure-related disorders.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Portal Instruments, Inc. is a clinical-stage medical device company based in Cambridge, Massachusetts, founded in 2012. The company specializes in developing needle-free jet injectors that deliver medications through the skin without the use of needles. Its innovative platform technology allows for the precise administration of drugs at specific depths and volumes, accommodating various drug viscosities and compositions. This painless and silent delivery method aims to enhance the patient experience and replace traditional needles and syringes. Portal Instruments is focused on creating customizable solutions for a wide range of applications, including medical, agricultural, and cosmetic uses, positioning itself to transform modern drug delivery practices.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Immune Design Corp., a clinical-stage immunotherapy company based in Seattle, Washington, focuses on enabling the body's immune system to combat diseases, with a primary emphasis on cancer treatment. The company leverages its ZVex and GLAAS discovery platforms to develop innovative therapies. Its lead product candidate is G100, currently in Phase II clinical trials for treating follicular non-Hodgkin lymphoma, both as a monotherapy and in combination therapy. Immune Design has collaboration and license agreements with Sanofi Pasteur. The company was founded in 2008 and operates under the umbrella of Merck & Co., Inc.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Pluromed, Inc., founded in 2003 and based in Woburn, Massachusetts, develops, manufactures, and markets disposable medical devices utilizing reverse thermosensitive polymer technology. The company's product portfolio includes the LeGoo Internal Vessel Occluder for temporary blood vessel occlusion, LeGoo Endovascular Occlusion Gel for clampless vascular and cardiovascular surgery, BackStop to prevent stone migration during ureteroscopic lithotripsy, and Lumagel for various cancer therapies and surgical procedures. These devices are designed to control bleeding during surgeries such as cardiac and vascular operations, plastic and reconstructive surgeries, kidney and liver cancer treatments, and trauma/battlefield injuries.

Melinta Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing novel antibiotics to combat drug-resistant infections. Its portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, treating various bacterial infectious diseases. The company's mission is driven by the urgent need for new therapies against antibiotic-resistant pathogens.

Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development of genomic technology to discover drugs derived from natural sources. Founded in 2010, the company has created a proprietary genomic search engine that utilizes customized search queries to identify hidden natural products based on their unique genomic signatures. This innovative approach enables researchers to uncover novel drug candidates and analyze their mechanisms of action, facilitating the conversion of genomes into therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.

Esperance Pharmaceuticals Inc. is a biotechnology company focused on developing targeted anticancer drugs aimed primarily at treating ovarian and breast cancer in women. Founded in 2005 and based in Houston, Texas, the company is advancing its lead product, EP-100, an oncolytic peptide designed to selectively attack and destroy cancer cells that express luteinizing hormone releasing hormone (LHRH) receptors. This innovative approach enables the drug to kill cancer cells, including those resistant to traditional chemotherapeutics, while sparing normal cells. Esperance Pharmaceuticals has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, enhancing its potential impact in oncology.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Nepentes Pharma Sp. z o.o. is a pharmaceutical company focused on the manufacturing and distribution of various healthcare products, including Iwostin, Emolium, Elixine, Propodia, ApiPanten, Propolki, and Propolets. The company is dedicated to enhancing brand presence in pharmacies by coordinating the development, implementation, and oversight of effective marketing strategies. Operating primarily in Central and Eastern Europe, Nepentes Pharma aims to provide high-quality products while ensuring optimal market performance through comprehensive business activities.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Medley, the third-largest pharmaceutical firm in Brazil, and the number one generic drugs group in the country.

Zentiva is a prominent generics company based in Europe, recognized as the third largest in the region and noted for its rapid growth. The company's roots trace back to the 15th century, reflecting a long-standing history in the pharmaceutical industry. Zentiva specializes in the manufacture of medicines and is actively involved in research and development to enhance its product offerings. As a valued partner in the generics market, Zentiva is dedicated to providing accessible and effective healthcare solutions.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.